Pharmaceutical

Neuvivo makes bid to enter ALS arena with immunotherapy...

NP001 is designed to tackle the neurodegenerative disease through an immunologic...

EMA starts review into hair loss drugs about potential ...

The safety review was requested by the French medicines agency, citing new safet...

Oncolytics targets accelerated approval for oncolytic v...

The company intends to start a registrational Phase II trial of pelareorep and c...

Activist investor Starboard forges $1bn stake in Pfizer...

US hedge fund Starboard now holds 0.6% of Pfizer’s value as the drugmaker strugg...

ProductLife boosts drug development with IntiQuan acqui...

ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm ...

Health Canada approves Telix’s Illuccix label expansion

Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix f...

OnKure and Reneo Pharmaceuticals complete merger

OnKure has announced the successful completion of its merger with Reneo Pharmace...

NUHS’s CD7 CAR-T cell therapy shows promise for leukaemia

The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with...

Teva and mAbxience partner to develop biosimilar candid...

Teva Pharmaceuticals International and mAbxience have entered into a worldwide l...

BMS receives FDA approval for Opdivo to treat NSCLC

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Admin...

Resilience secures funds to enhance production of essen...

National Resilience’s subsidiary Resilience Government Services has received aro...

A rational design approach to RNA targeting could repla...

At ELRIG 2024, Dr. Maria Duca described how her lab’s rational design approach b...

WuXi debates sale of pharma operations as BIOSECURE Act...

WuXi is considering the sale of some US and European operations to mitigate the ...

The benefits of using a nimble platform from phase to p...

It is common for sponsors to switch digital platforms between clinical trial pha...

FDA lifts clinical hold on Avidity’s lead antibody conj...

Two years after the FDA placed partial clinical hold, Avidity can resume researc...